Vitamin D Deficiency is Correlated with Poor Outcomes in Patients with Luminal-type Breast Cancer

Kim, Hee Jeong; Lee, Yu Mi; Ko, BeomSeok; Lee, Jong Won; Yu, Jong Han; Son, Byung Ho; Gong, Gyungyub; Kim, Sung‐Bae; Ahn, Sei Hyun

doi:10.1245/s10434-010-1465-6

Cited by 78 publications

(56 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally, the observation that the patients with HER2-/ HR? tumors were more likely to have vitamin D insufficiency already at baseline might be important given the recent description of the association between vitamin D insufficiency and poor prognosis mainly in luminal-like breast cancers [58].…”

Section: Discussionmentioning

confidence: 97%

Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy

Jacot

Pouderoux

Thézenas³

et al. 2012

Breast Cancer Res Treat

View full text Add to dashboard Cite

Patients with locally advanced breast cancer treated with neoadjuvant chemotherapy are at risk of cancer treatment-induced bone loss and consequently of increased skeletal morbidity. In addition, this situation could be worsened by the fact that only a minority of patients with breast cancer have sufficient vitamin D. A comprehensive evaluation of bone homeostasis is critical in this context. We retrospectively evaluated the serum levels of calcium, vitamin D, TRAIL, RANK ligand (RANKL), Osteoprotegerin (OPG), Bone TRAP, CrossLaps and DKK1 in 77 patients (median age: 50 years; range 25-74), with locally advanced breast cancer treated in our institute with anthracyclines-taxane neoadjuvant chemotherapy (7 cycles of 21 days/each) between March 2007 and August 2008. Serum samples were collected before the first (baseline) and the last treatment cycle. Variations and correlations between biomarker levels were evaluated. At baseline, 79.5 % of patients had vitamin D insufficiency (<30 ng/ml), increasing to 97.4 % at the end of the neoadjuvant chemotherapy (p < 0.0001). Calcium and RANKL serum concentrations were also significantly decreased, while OPG was significantly increased, resulting in lower RANKL/OPG ratio. Calcium and vitamin D, RANKL and vitamin D and RANKL and OPG levels were significantly correlated (Spearman's coefficient r = 0.2721, p = 0.0006; r = 0.1916, p = 0.002; and r = -0.179, p = 0.03, respectively). Nearly all included patients suffered from vitamin D insufficiency by the end of the neoadjuvant chemotherapy with changes in the calcium/RANKL/OPG axis that are evocative of deregulation of a functional regulatory mechanism. Further studies are needed to determine how drugs modulate this regulatory mechanism to preserve bone homeostasis in patients with breast cancer.

show abstract

Section: Discussionmentioning

confidence: 97%

Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy

Jacot

Pouderoux

Thézenas³

et al. 2012

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Other breast cancer outcomes include distant disease-free survival (16,18,19), disease-free survival (19,21), and relapse (19,20). Circulating 25-OHD concentrations were associated with longer distant disease-free survival (16,18,19).…”

Section: Breast Cancermentioning

confidence: 99%

“…Hence, an in-depth investigation of how tumor characteristics and lifestyle factors modify the associations of vitamin D with prognosis is needed. Only two of the six breast cancer studies reported analyses stratified by stage at diagnosis and hormone receptor status (18,21), one with BMI (18), and none with race. Of particular importance and interest is to determine whether part of the racial and obesityrelated differences in cancer survival can be explained by differences in the 25-OHD levels.…”

Section: The Role Of Tumor Characteristics and Lifestyle Factorsmentioning

confidence: 99%

Circulating 25-hydroxyvitamin D Levels and Prognosis among Cancer Patients: A Systematic Review

Toriola

Nguyen

Scheitler

et al. 2014

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Circulating 25-hydroxyvitamin D (25-OHD) is associated with a reduction in risk of some cancers, but its association with prognosis among patients with cancer is poorly understood. In view of the increasing number of cancer survivors in the United States and the high prevalence of vitamin D deficiency among patients with cancer, an evaluation of the role of circulating 25-OHD in prognosis among patients with cancer is essential. We conducted a systematic review of studies published in the following databases-PubMed, OvidSP, BioMed Central, EMBASE, and Scopus till September 2013 using the following search terms: "vitamin D," "25-hydroxyvitamin D," "calcidiol," "cancer," "survival," "mortality," and "prognosis." Our search yielded 1,397 articles. From the 1,397 articles, we identified 26 studies that evaluated the associations of circulating 25-OHD with prognosis among patients with cancer. Evidence suggests that circulating 25-OHD levels may be associated with better prognosis in patients with breast and colorectal cancer, but there is a paucity of information on its association with prognosis in other cancers. This review highlights the need for further studies evaluating the role of vitamin D in prognosis among patients with cancer. Cancer Epidemiol Biomarkers Prev; 23(6); 917-33. Ó2014 AACR.

show abstract

“…luminal type but they have not explained any mechanism for ER negative cancers. [15] However, In a recent study, it was shown that by upregulating the vitamin d receptors in murine model of TNBC, antiproliferative effect is enhanced [16] and thus explaining the effect of vitamin D in TNBC subtype breast cancer. Further studies explaining the exact molecular mechanism underlying such observations needs to be carried out.…”

Section: Discussionmentioning

confidence: 99%

Prognostic evaluation of vitamin D deficiency in breast cancer patients: a pilot study in India

Goyal

Garg²

2017

APALM

View full text Add to dashboard Cite

Background: Vitamin D deficiency has been associated with poor prognosis in breast cancer. A new molecular classification of breast cancer is being increasingly used that is based on expression of estrogen receptors, progesterone receptors and Her2/neu amplification and is found to correlate well with prognosis and outcome of disease. The present study was designed to determine serum vitamin D deficiency in these molecular subtypes of breast cancer. Methods:Estimation ofserum vitamin D levels by chemiluminiscence was done in a cohort of 99 breast cancer patients and 25 age matched healthy controls. Breast cancer patients were further grouped into luminal A, luminal B, Her2/neu enriched and triple negative subtypes based on immunohistochemistry results. Non-parametric tests were performed to compare vitamin D levels in different groups.Results: 54.6%, 60%, 66.6% and 84.2% of patients with luminal A, luminal B, Her2/neu enriched and triple negative subtypes respectively were found to be vitamin D deficient (<20ng/mL) as compared to only 20% in healthy controls. More aggressive Her2/neu enriched and triple negative subtype patients had significantly lower serum vitamin D levels than the luminal subtypes of breast cancer. Conclusion:Vitamin D deficiency is more prevalent and significantly lower levels are found in more aggressive subtypes of breast cancer. Vitamin D supplementation must be considered in these forms of breast cancer to improve outcome.

show abstract

Vitamin D Deficiency is Correlated with Poor Outcomes in Patients with Luminal-type Breast Cancer

Cited by 78 publications

References 27 publications

Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy

Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy

Circulating 25-hydroxyvitamin D Levels and Prognosis among Cancer Patients: A Systematic Review

Prognostic evaluation of vitamin D deficiency in breast cancer patients: a pilot study in India

Contact Info

Product

Resources

About